References

  1. Moshe Rogosnitzky, Rachel Danks, Therapeutic potential of the biscoclaurine alkaloid, cepharanthine, for a range of clinical conditions, Pharmacological reports: PR 63(2):337-47, March 2011.
  2. Zhang CH, Wang YF, Liu XJ, Lu JH, Qian CW, Wan ZY, Yan XG, Zheng HY, Zhang MY, Xiong S, Li JX, Qi SY, Antiviral activity of cepharanthine against severe acute respiratory syndrome coronavirus in vitro.Chin Med J (Engl). 2005 Mar 20;118(6):493-6.
  3. Natural Bis-Benzylisoquinoline Alkaloids-Tetrandrine, Fangchinoline, and Cepharanthine, Inhibit Human Coronavirus OC43 Infection of MRC-5 Human Lung Cells. Biomolecules. 2019;9(11):696. Published 2019 Nov 4.
  4. Kikukawa Y, Okuno Y, Tatetsu H, Nakamura M, Harada N, Ueno S: Induction of cell cycle arrest and apoptosis in myeloma cells by cepharanthine, a biscoclaurine alkaloid. Int J Oncol, 2008, 33, 807–814.
  5. Kakehi Y, Yoshida O, Segawa T, Kanematsu A, Hiura M, Shichiri Y: Intraarterial chemotherapy for metastatic renal cell carcinomas: combination with MDR-overcoming agents. Hinyokika Kiyo, 1994, 40, 925–929.
  6. Tsunemori H, Kitamura Y, Taniguchi S, Okazoe H, Taoka R, Inui M, Sugimoto M, Kakehi Y: Experience using intra-arterial chemotherapy in combination with MDR-reversing agent for bone and soft-tissue metastases from renal cell carcinoma (Japanese). Nish J Urol, 2008, 70, 245–249.
  7. Ohta T, Morita K: Effect of cepharanthin on radiotherapy induced leukopenia. Rinsho Hoshasen, 1990, 35, 471–474.
  8. Tsukikawa S, Oikawa H, Satoh T, Morikubo M, Komori- yama H, Hagiwara M: The effect of cepharanthin on adjuvant chemotherapy induced bone marrow suppression in patients with breast cancer. Gan To Kagaku Ryoho.1990, 17, 645–648.
  9. Song Y, Xia W, Jiang J, Wang Q: Reversal of multidrug resistance in drug-resistant cell line EAC/ADR by cepharanthine hydrochloride and its mechanism. Yao Xue Xue Bao, 2005, 40, 204–207.
  10. Ushiki N, Jobo T, Shimoda T, Kuramoto H, Arai M: Effects of cepharanthin on leukopenia and thrombocytopenia caused by CDDP-ACR-CPA therapy of ovarian cancer. Gan To Kagaku Ryoho, 1988, 15, 2701–2706.
  11. Asukai K, Kimura A, Gorai I, Uemura T, Minaguchi H: Effects of massive administration of cepharanthin on chemotherapy-induced leukopenia. Gan To Kagaku Ryoho, 1989, 16, 2583–2587.
  12. Saito R, Tsuchiya S, Ishizuka T, Fueki N, Ezawa K, Minato K: Clinical effects of cepharanthin on leukopenia by chemotherapy in lung cancer patients. Nippon Gan Chiryo Gakkai Shi, 1989, 24, 2587–2593.
  13. Suzuki R, Hara M, Shindoh J, Matsumoto S, Noda Y, Gonda H: Effects of cepharanthin on leukopenia and thrombocytopenia induced by chemotherapy in lung cancer patients. Gan To Kagaku Ryoho, 1992, 19, 647–652.
  14. Hibasami H, Takaji S, Murata T, Nakashima K: Cepharanthine potentiates the antitumor effect of methyl-glyoxalbis (cyclopentyl-amidino-hydrazone) on human leukemia cells. Anticancer Res, 1991, 11, 1543–1547.
  15. Kato T, Suzumura Y: Potentiation of antitumor activity of vincristine by the biscoclaurine alkaloid cepharanthine. J Natl Cancer Inst, 1987, 79, 527–532.
  16. Abe T, Koike K, Ohga T, Kubo T, Wada M, Kohno K: Chemosensitization of spontaneous multidrug resistance by a 1,4-dihydropyridine analogue and verapamil in hu- man glioma cell lines overexpressing MRP or MDR1. Br JCancer, 1995, 72, 418–423.
  17. Enokida H, Gotanda T, Oku S, Imazono Y, Kubo H, Hanada T: Reversal of P-glycoprotein-mediated paclitaxel resistance by new synthetic isoprenoids in human bladder cancer cell line. Jpn J Cancer Res, 2002, 93, 1037–1046.
  18. Nakajima A, Yamamoto Y, Taura K, Hata K, Fukumoto M, Uchinami H: Beneficial effect of cepharanthine on overcoming drug-resistance of hepatocellular carcinoma. Int J Oncol, 2004, 24, 635–645.
  19. Fujimura T, Shibata H, Maekawa I, Furusawa S, Kawauchi H, Sasaki K: Reversal of resistance to doxorubicin with cepharanthine in murine P388 leukemia cells. Jpn J Pharmacol, 1990, 54, 464–467.
  20. Furusawa S, Wu J: The effects of biscoclaurine alkaloid cepharanthine on mammalian cells: implications for cancer, shock, and inflammatory diseases. Life Sci, 2007, 80, 1073–1079.
  21. Mukai M, Che X, Furukawa T, Sumizawa T, Aoki S, Ren X: Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells. Cancer Sci, 2003, 94, 557–563.
  22. Shiraishi N, Akiyama S, Nakagawa M, Kobayashi M, Kuwano M: Effect of bisbenzylisoquinoline (bisco-claurine) alkaloids on multidrug resistance in KB human cancer cells. Cancer Res, 1987, 47, 2413–2416.
  23. Shimazu R, Tanaka G, Tomiyama R, Kuratomi Y, Inokuchi A: Cepharanthin effect on radiation-induced xerostomia and taste disorder in patients with head and neck cancer. Nippon Jibiinkoka Gakkai Kaiho, 2009, 112,648–655.
  24. Azuma M, Aota K, Tamatani T, Motegi K, Yamashita T, Ashida Y: Suppression of tumor necrosis factor alpha induced matrix metalloproteinase 9 production in human salivary gland acinar cells by cepharanthine occurs via down-regulation of nuclear factor kappaB: a possible therapeutic agent for preventing the destruction of the acinar structure in the salivary glands of Sjögren’s syndrome patients. Arthritis Rheum, 2002, 46, 1585–1594.
  25. Tomoko Yamanoi, Keiko Aota, Yukihiro Momota, Masayuki Azuma,Treatment with the Biscoclaurine Alkaloid Cepharanthine Significantly Increases Salivary Secretion in Primary Sjögren's Syndrome Patients,Journal of Oral Health and Biosciences,2017 Volume 29 Issue 2 Pages 39-48.
  26. Takahata M, Hashino S, Fujimoto K, Endo T, Kobayashi N, Kurosawa M, Iwasaki H, Miyake T, Kohda K, Maekawa I, Sasagawa H, Tsustumi Y, Miyagishima T, Tanaka J, Imamura M, Teshima T,Clinical efficacy of high-dose cepharanthine for idiopathic thrombocytopenic purpura: retrospective multicenter analysis,Rinsho Ketsueki. 2012 Dec;53(12):1983-90.
  27. Yamazaki T, Shibuya A, Ishii S, Miura N, Ohtake A, Sasaki N, Araki R, Ota Y, Fujiwara M, Miyajima Y, Uetake K, Hamahata K, Kato K, Kawakami K, Toyoda H, Moriguchi N, Okada M, Nishi M, Ogata Y, Takimoto T, Ohga S, Ohta S, Amemiya S,High-dose Cepharanthin for pediatric chronic immune thrombocytopenia in Japan, Pediatr Int. 2017 Mar;59(3):303-308.
  28. Nakayama, S & Matsushita, A & Ichiba, S & Nagai, K. Clinical evaluation of cepharanthin for chronic idiopathic thrombocytopenic purpura, The Japanese journal of clinical hematology. 33. 408-9. 1992
  29. Nishida H, Tsuchiya H: Nodular muscular sarcoidosis vanished during oral cepharanthine treatment. Cent Jap J Orthopaed Surg Traum, 2007, 50, 1133–1134.
  30. Niwa Y: Effect of cepharanthine on alopecia areata. Hifuka Kiyo, 1969, 64, 47–52.
  31. Morita K, Nakamura M, Nagamachi M, Kishi T, Miyachi Y: Seventeen cases of alopecia areata: combination of SADBE topical immunotherapy with other therapies. J Dermatol, 2002, 29, 661–664.
  32. Inui S., Tohyama C. and Itami S., Acceleration of Hair Growth Rate by Topical Liposomal Cepharanthine in Male Androgenetic Alopecia.,Department of Regenerative Dermatology, Osaka University School of Medicine.
  33. Gülçin I, Elias R, Gepdiremen A, Chea A, Topal F: Antioxidant activity of bisbenzylisoquinoline alkaloids from Stephania rotunda: cepharanthine and fangchinoline. J Enzyme Inhib Med Chem, 2010, 25, 44–53.
  34. Chea A, Hout S, Bun S, Tabatadze N, Gasquet M, Azas N: Antimalarial activity of alkaloids isolated from Stephania rotunda. J Ethnopharmacol, 2007, 112, 132–137.
  35. Okamoto M, Okamoto T, Baba M: Inhibition of human immunodeficiency virus type 1 replication by combination of transcription inhibitor K-12 and other antiretroviral agents in acutely and chronically infected cells. Antimicrob Agents Chemother, 1999, 43, 492–497.